Latest Enantiopure drugs Stories
The Drug Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com. Dallas, TX (PRWEB) December 21, 2012 Online prescription drug resource center DrugRisk.com has added information to its already comprehensive database which indicates German drug maker Bayer may be stepping up efforts to resolve claims against Yaz and Yasmin birth control, possibly even paying more per case that before. “The...
The US Drug Watchdog says, "If a woman used Yaz, Yasmin, or the generic version Ocella birth control pills, and then suffered a severe side effect like a heart attack, pulmonary embolism, stroke or blood clotting we want them to call the Johnson Law Group right away.” According to the September 17th 2009 edition of the New York Times, "The FDA released a warning letter sent in September to Bayer Pharmaceuticals over Yaz & Yasmin. The FDA letter was very critical of the drug...
A U.S. Food and Drug Administration-funded study led by the Kaiser Permanente Northern California Division of Research found an increased risk of arterial thrombotic events (ATE) and venous thromboembolic events (VTE) — commonly referred to as blockage of arteries and blood clots, respectively — associated with drospirenone-containing birth control pills compared to four low-dose estrogen combined hormonal contraceptives. "We found that starting use of drospirenone-containing combined...
ALISO VIEJO, Calif., Sept. 20, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced several business updates. The highlights are being provided in connection with the company's presentation today at the UBS Global Life Sciences Conference in New York City. Highlights include: Exceeding 10,000 total NUEDEXTA® prescriptions for the month of August. NUEDEXTA prescriptions of 10,710 in August represent 9% growth over the month of July. August monthly...
PHILADELPHIA, October 29, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in patients who have had residual symptoms of depression following treatment with LEXAPRO(R) (escitlopram) for Major Depressive Disorder (MDD). Based on these findings, Shire intends to advance discussions with regulators to explore...
OSAKA, Japan, Aug. 22 /PRNewswire-FirstCall/ -- Hospira Japan Co., Ltd. today announced it has received an approval for the long-term (greater than 24 hour) use of the sedative "Precedex IV(TM)200ug" (generic name: dexmedetomidine hydrochloride). This approval follows Hospira's first launches earlier this year of Precedex in Canada and in South Korea, important milestones for Hospira as the company continues to build the molecule's global presence. Originally, Precedex was approved in...
FORT LEE, N.J., March 10 /PRNewswire/ -- Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA) recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review. "We are pleased that the lurasidone NDA has been accepted for...
Although the increasing use of smart drugs known as "nootropics" will be hard to ban, it could lead to the use of routine doping tests for exam students, according to a report issued Wednesday.Writing in the Journal of Medical Ethics, Vince Cakic of the Department of Psychology at the University of Sydney pointed to the abuse of smart drugs among students wanting to achieve higher academic standing.Cakic compares the situation to the controversial use of performance drugs in professional...
ATLANTA, April 10 /PRNewswire/ -- Once-daily Keppra XR(TM) (levetiracetam) extended-release tablets are now available in a new dosage strength--750 mg--enabling doctors to simplify patients' treatment plans by decreasing the number of tablets they take each day. (Photo: http://www.newscom.com/cgi-bin/prnh/20090410/NY97244 ) According to studies published in Epilepsy & Behavior and Neurology, patients are more likely to adhere to their medication regimen when it is taken once daily,...
U.S. authorities accused a New York pharmaceutical company Wednesday of making false claims about two antidepressants it markets for unapproved pediatric use. The civil complaint unsealed in U.S. District Court in Massachusetts, not only alleges Forest Laboratories Inc. marketed Celexa and Lexapro improperly but that it paid kickbacks to doctors to prescribe them. The U.S. attorney's office alleges the company's illegal promotional tactics caused thousands of false and fraudulent claims to...
